← Browse by Condition
Medical Condition

neoplasm metastases

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1

ClinicalMetric tracks all active clinical trials for neoplasm metastases sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — neoplasm metastases Clinical Trials

How many clinical trials are currently recruiting for neoplasm metastases?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for neoplasm metastases, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neoplasm metastases?
neoplasm metastases research spans Phase 1 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neoplasm metastases clinical trial?
Eligibility criteria for neoplasm metastases trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Top Sponsors
Lithuanian University of Health Sciences 1 trial
M.D. Anderson Cancer Center 1 trial
Imperial College London 1 trial

Recruiting Clinical Trials

NCT07863986
Recruiting
Predictive Factors for Response to Lutetium-177 PSMA Radioligand Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment
70 pts
Location
Lithuania
Sponsor
Lithuanian University of Healt...
View Trial →
NCT03911388 Phase 1
Recruiting
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Enrollment
24 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT02246634
Recruiting
Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)
Enrollment
282 pts
Location
United Kingdom
Sponsor
Imperial College London
View Trial →

Related Conditions

prostate cancer (1) prostatic neoplasms (1) prostatic neoplasms castration resistant (1) neoplasms brain (1) glioblastoma multiforme (1) glioblastoma of cerebellum (1) neoplasms (1) astrocytoma (1) astrocytoma cerebellar (1) neuroectodermal tumors (1) neuroectodermal tumors primitive (1) cerebellar pnet childhood (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology